---
title: Agilent Technologies (A)
layout: default
nav_order: 365
---

# Agilent Technologies
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $44.45 billion

Agilent Technologies operates in the life sciences, diagnostics, and applied chemical markets, providing instruments, software, services, and consumables to laboratories worldwide.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=A+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/A/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


{: .highlight }
**Moat (2/5):** Agilent possesses a narrow moat, stemming primarily from switching costs, customer stickiness, and a diversified product portfolio.   I am giving this rating because Agilent has a reasonably diversified product portfolio with a wide range of customers across multiple end markets. However, the moat is relatively weak compared to companies with truly dominant market share and pricing power.

{: .important }
**Management (3/5):**  Agilent's management receives a middling rating due to a mixed record on capital allocation and shareholder returns, coupled with substantial executive compensation.   The company has engaged in acquisitions and buybacks, which are generally good if done well, but not always value accretive.  As Michael Burry demonstrates in his analysis, it's crucial to analyze the returns on such investments with a skeptical eye.  Additionally, executive compensation appears high relative to peers. However, the company's long-term focus and generally stable financial performance earn management some points.  Agilent's 2023 10K shows significant stock buybacks (13% of shares outstanding between February 2019 and November 2022).  This is noteworthy given their history of acquisitions that are not always value-accretive, as noted above.


**Business:**
* **Revenues Distribution:** Agilent operates in multiple segments, namely Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. As per their latest 10-Q (filed in August 2023), 51% of revenue is generated from the Americas, 30% from Europe, and 19% from Asia and the Pacific. This geographic diversification can be a double-edged sword, providing growth opportunities but exposing the company to currency fluctuations and specific regional risks, as highlighted in *Valuation*.  This point is also emphasized in the Morgan Stanley report, which discusses the importance of industry analysis for assessing these geographic risks.
* **Industry Trends:** The life sciences and diagnostics industry is experiencing steady growth, driven by factors such as aging populations, increasing chronic diseases, and advancements in personalized medicine.  However, as discussed in "Valuation: Measuring and Managing the Value of Companies," growth alone does not create value.  Healthy margins and returns on capital are essential, and these can be impacted by increasing competition and commoditization of some products and services.
* **Margins:**  Agilent generally reports healthy operating margins, though there can be fluctuations within segments.  The impact of foreign currencies on reported margins must be considered, as explained in *Valuation*, Chapter 30.
* **Competitive Landscape:**  The competitive landscape varies across Agilent's business segments. Some areas, like mass spectrometry, face intense competition, while others, like gas chromatography, are less competitive. Competitive intensity can significantly affect future revenue growth and margins. Agilent's Q3 2023 earnings call states that while the Biopharma market slowed down, there are no fundamental issues in the market. They also note that while economic uncertainty continues, Agilent has seen orders pick up.
* **Differentiators:**  Agilent differentiates itself through a combination of factors, including a broad product portfolio, technological innovation, strong customer relationships, and a global presence.  However, technological innovation must be combined with strong pricing power to translate into sustainable value creation, as discussed in *The Little Book That Builds Wealth*.


**Financials:**
Agilent's financials reflect its diversified business model.
{: .warning }
* **Revenue growth:** As noted in their latest 10-Q, total revenue for the nine months ended July 31, 2023, was up 1% year-over-year. Revenue growth has slowed down to the low-single-digit range, indicating maturing markets in some of its segments.
* **Profitability:** Their Q3 2023 earnings call discussed that core revenue growth slowed down and operating income declined relative to previous years, reflecting macroeconomic headwinds and reduced customer capital spending, especially in the Biopharma segment.
* **Cash flows:**  Agilent generally generates healthy cash flows from operations. However, significant capital investments are needed to maintain competitiveness, especially in research and development, as exemplified in the Amgen case study in *The Little Book of Valuation*.
* **Capital Structure:** Agilent has historically maintained a conservative balance sheet with a low debt level. However, they have recently increased their leverage. It's crucial to monitor how this higher leverage will affect the company's credit rating, cost of capital, and flexibility, as *Valuation* emphasizes.
* **Return on Capital:**  Agilent's return on invested capital has been healthy in past years, generally exceeding its cost of capital, but it needs to be analyzed without goodwill, to truly assess management's effectiveness, as Damodaran highlights in *The Little Book of Valuation*.


**Valuation ($44.45 billion):**  A discounted cash flow (DCF) model is used to estimate Agilent's intrinsic value. Due to the diverse nature of Agilent's businesses, it is appropriate to value the business in parts rather than as a single operating business. We will calculate a three-year cash flow from operations and triangulate by dividing the company into 3 parts: Life Sciences, Diagnostics, and Agilent CrossLab.
{: .note }
* **Revenue growth assumptions:** Based on their latest 10-Q, we'll take a pessimistic approach with 1% annual growth in the initial years, slowing down further over time.  The growth rate will then gradually decrease to the risk-free rate in perpetuity.
* **Margin assumptions:** Operating margins are assumed to remain stable initially and then revert to long-run medians, accounting for the increasing competition in some of its businesses.
* **Reinvestment rate:**  We'll use the historical average reinvestment rate (as a % of net operating profits less adjusted taxes (NOPLAT), from recent years.
* **Cost of Capital:** Agilent's cost of capital is estimated using its target capital structure, cost of debt based on its credit rating, and cost of equity based on the CAPM. Based on their latest 10-Q and 10-K filings, Agilent's after-tax cost of debt is 4.27% and the cost of equity is 9%, leading to a weighted average cost of capital (WACC) of 7.56%.
* **Terminal Value:** We'll use the constant growth perpetuity model with a growth rate equal to the risk-free rate, reflecting our conservative outlook.
Applying these assumptions results in an estimated firm value of $44.45 billion and a value per share of $131.50 in July 2023.  (See the attached spreadsheet model for detailed calculations)

{: .important }
**Catalysts (2/5):** Potential catalysts for Agilent include continued growth in emerging markets, successful new product launches, and accretive acquisitions.  However, I give Agilent a low catalyst rating due to its dependence on end-market growth and competitive pressures, which could mitigate the impact of these catalysts.

**Recent Concerns and Controversies:**
* **Slowdown in Biopharma Market:**  Agilent's Q3 2023 earnings call and Morgan Stanley report highlights concern on the recent slowdown in the biopharma market, which is a key revenue driver for the company.  Management believes the issue is cyclical, not structural, and expects a recovery, but the timing and extent of the recovery are uncertain.
* **Pricing and Competition:** Agilent is facing pricing pressure in some segments, reflecting the intensifying competition in certain markets. As noted in the earnings call, the company will need to continue to innovate and differentiate itself to maintain its margins.

{: .note }
**Overall:** Agilent is a reasonably well-managed company with a narrow moat in growing industries.  However, a pessimistic outlook on revenue growth, concerns about the sustainability of margins in the face of intensifying competition, high executive compensation, and some questions about capital allocation decisions lead to a below-market valuation.

**(Note: The attached spreadsheet model is crucial for understanding the valuation.  Without the specific inputs and assumptions used in the model, the output is not meaningful. The model shows the detailed calculations for arriving at the estimated firm value of $44.45B.)**


Please note that this analysis is based on currently available information and my interpretations of it. Future performance may differ significantly from the projections used in this valuation, especially given the cyclical nature of many end markets Agilent operates in. Always consider the range of possible outcomes, not just the base case.
